TMPRSS11D and mastocytosis: However, systematic screening for HαT in future clinical trials—including both non-advanced and advanced subtypes of mastocytosis—appears crucial, as HαT could potentially influence treatment response and might eventually guide personalized therapeutic strategies depending on the type of medication used (e.g., biologics, tyrosine kinase inhibitors).